Use of Asthma Medication During Gestation and Risk of Specific Congenital Anomalies

Ruth P Cusack; Christiane E Whetstone; Gail M Gauvreau

doi:10.1016/j.iac.2022.07.007

Use of Asthma Medication During Gestation and Risk of Specific Congenital Anomalies

Immunol Allergy Clin North Am. 2023 Feb;43(1):169-185. doi: 10.1016/j.iac.2022.07.007. Epub 2022 Oct 28.

Authors

Ruth P Cusack¹, Christiane E Whetstone², Gail M Gauvreau³

Affiliations

¹ Department of Medicine, McMaster University, HSC 3U31 F, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
² Department of Medicine, McMaster University, HSC 3U20, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
³ Department of Medicine, McMaster University, HSC 3U31E, 1200 Main Street W, Hamilton, Ontario L8N 3Z5, Canada. Electronic address: gauvreau@mcmaster.ca.

PMID: 36411002
DOI: 10.1016/j.iac.2022.07.007

Abstract

Poorly controlled asthma can affect neonatal outcomes including congenital anomalies, which can be reduced with appropriate asthma care during pregnancy. Although there is a concern regarding the safety of asthma medication use during pregnancy and congenital anomalies, the risk of uncontrolled asthma outweighs any potential risks of controller and reliever medication use. Patient education before and during pregnancy is critical to ensure good compliance to therapy and reduce the risk of poor asthma control.

Keywords: Asthma medication; Congenital anomaly; Pregnancy.

Publication types

Review

MeSH terms

Anti-Asthmatic Agents* / adverse effects
Asthma* / drug therapy
Asthma* / epidemiology
Female
Humans
Infant, Newborn
Pregnancy
Pregnancy Complications* / drug therapy
Pregnancy Complications* / epidemiology

Substances

Anti-Asthmatic Agents